Unicycive Therapeutics (Nasdaq: UNCY) announced resubmission of its 505(b)(2) New Drug Application (NDA) to the FDA for oxylanthanum carbonate (OLC), a phosphate binder for treating hyperphosphatemia in patients with chronic kidney disease on dialysis. A new PDUFA target date is expected in 1H 2026, within 30 days of the resubmission. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at b2idigital.com/unicycive. The resubmission reflects progress by the o

4.2K views · 797 reactions | Although the digital age has brought us benefits, there are drawbacks, especially for younger generations. Learning to manage and balance our online presence is essential, and a good way to start is to pause before we begin any activity. This helps us to observe and consider our actions, and to make the best decisions. @heartfulness #Daaji #Pause #Observe #Action #Decision | Kamlesh D Patel | Facebook

4.7K views · 33 reactions | Exciting news this week with Pfizer reporting their mRNA vaccine is 90% effective, based on their Phase III clinical trial data. Dr. Tom looks inside the virus to break down how mRNA vaccines work, and whether news this promising means we can finally relax. To interact with the content in this video, visit: coronavirus.biodigital.com To learn more about BioDigital or use the platform yourself, visit: biodigital.com #vaccine #COVID19 | BioDigital | Facebook

19K views · 661 reactions | Examples from past or previous experience is one thing. Communication on an issue or feelings revolving around said issue shouldn’t be used as weaponization | Kayley Whitfield | Facebook

197K views · 5.9K reactions | Alex Newman explains how the Digital ID...